Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Company profile
Ticker
ROG-SE, RHHBF
Exchange
Website
CEO
Severin Schwan
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
ROG-SE stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 Apr 23
F-6
Registration for ADRs (foreign)
21 Mar 23
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
17 Nov 16
SC TO-C
Information about tender offer
12 Jan 15
F-6EF
Automatic registration for ADRs (foreign)
10 Feb 14
DFAN14A
Additional proxy materials by non-management
12 Apr 12
DFAN14A
Additional proxy materials by non-management
11 Apr 12
DFAN14A
Additional proxy materials by non-management
6 Apr 12
DFAN14A
Additional proxy materials by non-management
4 Apr 12
DFAN14A
Additional proxy materials by non-management
3 Apr 12
Latest ownership filings
3
Aligos Therapeutics, Inc.
7 Nov 23
4
Jasper Therapeutics, Inc.
26 Jan 23
4
Entrada Therapeutics, Inc.
4 Nov 21
3
Entrada Therapeutics, Inc.
28 Oct 21
3
Jasper Therapeutics, Inc.
4 Oct 21
4
Pandion Therapeutics, Inc.
23 Jul 20
3
Pandion Therapeutics, Inc.
16 Jul 20
3
Spark Therapeutics, Inc.
18 Dec 19
SC 13D/A
Senseonics Holdings, Inc.
20 Mar 19
4
Foundation Medicine, Inc.
2 Aug 18
Institutional ownership, Q3 2023
16.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 76 |
Opened positions | 7 |
Closed positions | 10 |
Increased positions | 17 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 628.02 bn |
Total shares | 17.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Fisher Asset Management | 11.14 mm | $381.10 bn |
Saratoga Research & Investment Management | 2.27 mm | $76.97 bn |
Boston Common Asset Management | 534.20 k | $18.28 mm |
Sofos Investments | 517.46 k | $100.19 bn |
Kornitzer Capital Management | 254.65 k | $8.71 bn |
ONB Old National Bancorp | 251.84 k | $8.62 bn |
Hikari Power | 235.82 k | $8.00 mm |
Altrius Capital Management | 171.06 k | $5.80 bn |
SAMG Silvercrest Asset Management | 155.59 k | $5.32 bn |
Meritage Portfolio Management | 147.55 k | $5.01 mm |
News
Reported Earlier, Roche's Genentech Announced Data From Stage 1 Of The National Institutes Of Health (NIH)-Sponsored Pivotal Phase III Outmatch Study Evaluating The Efficacy And Safety Ofxolair®
26 Feb 24
Roche Collaborates With PathAI To Expand Digital Pathology Capabilities For Companion Diagnostics
13 Feb 24
Repare Therapeutics To Regain Global Development, Commercialization Rights To Camonsertib (RP-3500), As Roche Notified That, Effective May 7, 2024, It Is Terminating License And Collaboration Agreement
12 Feb 24
Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo® In Macular Edema Due To Branch And Central Retinal Vein Occlusion
1 Feb 24
Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
26 Jan 24